TY - JOUR
T1 - Lack of Effectiveness of Magnesium in Chronic Stable Asthma
T2 - A Prospective, Randomized, Double-blind, Placebo-Controlled, Crossover Trial in Normal Subjects and in Patients With Chronic Stable Asthma
AU - Bernstein, Wendy K.
AU - Khastgir, Terrance
AU - Khastgir, Anupa
AU - Hernandez, Efrain
AU - Miller, Jo Ann
AU - Schonfeld, Steven A.
AU - Nissim, Jack E.
AU - Chernow, Bart
PY - 1995/2/13
Y1 - 1995/2/13
N2 - Background: Magnesium sulfate has been helpful in the treatment of acute exacerbations of asthma. We hypothesized that magnesium would also be an effective bronchodilator in patients with chronic stable asthma. Methods: We performed a prospective, randomized, double-blind, placebo-controlled, crossover trial in 15 patients with chronic, stable asthma and 10 nonasthmatics. On study day 1, spirometry and albuterol challenge were used to confirm the presence of asthma according to American Thoracic Society criteria. On study day 2, subjects received intravenous magnesium sulfate (2 g) or placebo (saline). On study day 3, subjects were crossed over to receive the other drug. Spirometry was performed before, during, and after drug or placebo administration. Circulating ionized magnesium concentrations were determined before and after intravenous magnesium or placebo administration. Results: Magnesium infusion caused no statistically significant changes in forced expiratory volume in 1 second (mean±SEM, 1.92±0.13L before, 1.98±0.12L during, and 2.01±0.14 L after magnesium administration), forced vital capacity (mean±SEM, 3.44±0.25 L before, 3.60±0.26 L during, and 3.59±0.25 L after magnesium administration), or maximum forced expiratory flow rate (mean±SEM, 5.42±0.44 L/second before, 5.46±0.46 L/second during, and 5.57±0.49 L/second after magnesium administration). Placebo caused no changes in these three physiologic variables. Conclusion: Magnesium is not effective as a bronchodilator in chronic, stable asthmatics or in normal non-asthmatic adults.
AB - Background: Magnesium sulfate has been helpful in the treatment of acute exacerbations of asthma. We hypothesized that magnesium would also be an effective bronchodilator in patients with chronic stable asthma. Methods: We performed a prospective, randomized, double-blind, placebo-controlled, crossover trial in 15 patients with chronic, stable asthma and 10 nonasthmatics. On study day 1, spirometry and albuterol challenge were used to confirm the presence of asthma according to American Thoracic Society criteria. On study day 2, subjects received intravenous magnesium sulfate (2 g) or placebo (saline). On study day 3, subjects were crossed over to receive the other drug. Spirometry was performed before, during, and after drug or placebo administration. Circulating ionized magnesium concentrations were determined before and after intravenous magnesium or placebo administration. Results: Magnesium infusion caused no statistically significant changes in forced expiratory volume in 1 second (mean±SEM, 1.92±0.13L before, 1.98±0.12L during, and 2.01±0.14 L after magnesium administration), forced vital capacity (mean±SEM, 3.44±0.25 L before, 3.60±0.26 L during, and 3.59±0.25 L after magnesium administration), or maximum forced expiratory flow rate (mean±SEM, 5.42±0.44 L/second before, 5.46±0.46 L/second during, and 5.57±0.49 L/second after magnesium administration). Placebo caused no changes in these three physiologic variables. Conclusion: Magnesium is not effective as a bronchodilator in chronic, stable asthmatics or in normal non-asthmatic adults.
UR - http://www.scopus.com/inward/record.url?scp=0028854970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028854970&partnerID=8YFLogxK
U2 - 10.1001/archinte.1995.00430030061006
DO - 10.1001/archinte.1995.00430030061006
M3 - Article
C2 - 7832598
AN - SCOPUS:0028854970
SN - 0003-9926
VL - 155
SP - 271
EP - 276
JO - Archives of internal medicine
JF - Archives of internal medicine
IS - 3
ER -